A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Na ve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: High-risk Diffuse Large B-cell Lymphoma
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1. Histologically-confirmed diagnosis of CD20-positive Diffuse Large B-Cell Lymphoma (DLBCL) 2. Able to swallow tablets
You may not be eligible for this study if the following are true:
-
1. Receiving, or has the subject received, any other radiation or systemic anticancer treatment for lymphoma 2. Known central nervous system (CNS) involvement 3. A second primary malignancy (except adequately treated non-melanoma skin cancer)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.